SIMABS

Agoralaan, Abis Abis /

3590 Diepenbeek

BE

SIMABS

Foundation date

22/08/2019

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

SIMABS is a start-up biotechnology venture that wants to develop a new bio-manufacturing platform to provide cost effective therapeutic monoclonal antibodies at small scale to biopharmaceutical companies.

Upcoming events

Latest news

  • Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies

    13 hours ago

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • FINTEPLA®▼ (fenfluramine) approved in Japan for the treatment of seizures associated with Dravet syndrome

    Tuesday September 27th 2022

Jobs by SIMABS